Drug Search Results
More Filters [+]

Crisantaspase

Alternative Names: crisantaspase, asparaginase, l-asparaginase, jzp-458, jzp 458, jzp458, erwinase, rylaze, eryaspase, elspar, erwinaze, Enrylaze
Latest Update: 2024-07-09
Latest Update Note: News Article

Product Description

Crisantaspase is an asparaginase enzyme produced by Erwinia chrysanthemi and used to treat acute lymphoblastic leukemia (ALL) in case of hypersensitivity to Escherichia coli l-asparaginase (ASNase). (Sourced from: https://pubmed.ncbi.nlm.nih.gov/30597637/)

Mechanisms of Action: Protein Synthesis Inhibitor

Novel Mechanism: No

Modality: Peptide/Protein

Route of Administration: Intravenous,Intramuscular

FDA Designation: Fast Track - Pancreatic Cancer *

Approval Status: Approved

Approved Countries: Algeria | Argentina | Austria | Bangladesh | Belgium | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Czech | Denmark | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Malta | Mexico | Morocco | Netherlands | New Zealand | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Taiwan | Thailand | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States

Approved Indications: Acute Leukemia | Acute Lymphoid Leukemia | Leukemia | Lymphoid Leukemia

Known Adverse Events: Thrombosis | Pancreatitis | Anaphylaxis | Hyperglycemia

Company: ERYtech Pharma
Company Location: LYON I0 69008
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Crisantaspase

Countries in Clinic: Australia, Austria, Belgium, Brazil, Canada, China, Czech Republic, Denmark, Finland, France, Germany, Hungary, Ireland, Israel, Italy, Netherlands, Norway, Poland, Portugal, Russia, Slovakia, Spain, Sweden, Switzerland, United Kingdom, United States

Active Clinical Trial Count: 17

Highest Development Phases

Phase 3: Acute Lymphoid Leukemia|Adenocarcinoma|Common Cold|Leukemia|Lymphoid Leukemia|Lymphoma|Lymphoma, Non-Hodgkin|Pancreatic Cancer|Precursor Cell Lymphoblastic Leukemia-Lymphoma

Phase 2: B-Cell Leukemia|Lymphoma, B-Cell|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

Phase 1: Pancreatic Ductal Carcinoma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

TINI 2

P2

Recruiting

Lymphoid Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma

2028-12-01

AIEOP-BFM ALL 2017

P3

Recruiting

Precursor Cell Lymphoblastic Leukemia-Lymphoma|Acute Lymphoid Leukemia

2028-07-14

AIEOP-BFM ALL 2017

P3

Active, not recruiting

Acute Lymphoid Leukemia

2028-06-07

LBL 2018

P3

Recruiting

Precursor Cell Lymphoblastic Leukemia-Lymphoma|Lymphoid Leukemia|Lymphoma, Non-Hodgkin

2027-11-22

Recent News Events